Is Bimekizumab included in medical insurance?

Bimekizumab (Bimekizumab) contains active substancesbimekizumab, is a drug used to treat inflammatory diseases after approval in the EU. It is administered once a month by subcutaneous injection and exerts its pharmacological effect by binding and inhibiting a pro-inflammatory cytokine involved in the pathogenesis. Currently approved indications include:

Moderate to severe plaque psoriasis (red, scaly patches on the skin) in adults who require systemic treatment (treatment with drugs that affect the whole body); and psoriatic arthritis (the joint inflammation that often accompanies plaque psoriasis) in adults who do not respond well to disease-modifying antirheumatic drugs (DMARDs) or who are unable to take these drugs; As well asadults with axial spondyloarthritis (inflammation of the spine causing back pain) who have not responded well to conventional treatments, for which it is used in patients who have signs of disease on X-rays (X-ray axial spondyloarthritis) and in patients who have clear signs of inflammation on X-rays but no signs of disease (non-X-ray axial spondyloarthritis). For psoriatic arthritis, bimeclizumab can be used alone or in combination with other drugs.

Bimeizumab's original drug has not yet been launched in China, so it cannot be included in medical insurance. The specific time when it will be launched in China is unclear. The European version of bimezumab original drug sold overseas, specifications160mg*2 per box may cost more than 40,000 yuan (the price may fluctuate due to the exchange rate). The price is still relatively high. There is currently no generic version of bimezumab produced and launched. For the specific price and drug information of this drug, please consult a medical consultant.